Clinical trials: Advanced Illness
Opioid-Induced Constipation
Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness
This is an open-label, multicenter extension of study 3200K1-4000-WW that will evaluate the safety of methylnaltrexone. This drug will be administered by subcutaneous injection and will be tested in late stage, advanced illness…
- Trial name
- NCT00672139
- Testing
- Methylnaltrexone bromide
- Where
- 46 sites in United States, Australia and 8 more
- Volunteers
- 156 people
- Sponsor
- Bausch Health Americas, Inc.
Cardiac Pacemaker, Cardiac Rhythm Disorder
LEAP 2 Chronic EFS
Prospective, single-arm, non-randomized, unblinded, chronic feasibility study designed to evaluate the safety and performance of the AVEIR™ Conduction System Pacing (CSP) Leadless Pacemaker system.
- Conditions
- Cardiac Pacemaker, Cardiac Rhythm Disorder, Bradycardia
- Trial name
- NCT07287423
- Testing
- AVEIR CSP Leadless Pacemaker System
- Where
- Czechia
- Volunteers
- 30 people
- Sponsor
- Abbott Medical Devices
Terminal Illness
Open-Label Treatment Extension of Protocol MNTX 301
This study is an open-label extension allowing patients who have completed Protocol MNTX 301 to continue to receive SC MNTX.
- Trial name
- NCT01367600
- Testing
- SC Methylnaltrexone (MNTX)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Bausch Health Americas, Inc.
Opioid-induced Constipation
Study of Methylnaltrexone in Opioid-Induced Constipation Patients
This is a multicenter, randomized, double-blind , placebo-controlled trail to investigate the safety and efficacy of subcutaneous methylnaltrexone for treating opioid-induced constipation in patients with advanced illness.
- Trial name
- NCT02574819
- Testing
- Methylnaltrexone (MNTX)
- Where
- 12 sites in China
- Volunteers
- 198 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Illness Patients With Opioid Induced Constipation
A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients
To test the effectiveness of MNTX in advanced illness subjects.
- Trial name
- NCT00401362
- Testing
- SC Methylnaltrexone
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Bausch Health Americas, Inc.
Opioid-Induced Constipation
Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness
This study will evaluate the safety and efficacy of methylnaltrexone administered as subcutaneous injections in subjects who have opioid-induced constipation and an advanced illness.
- Trial name
- NCT00672477
- Testing
- Methylnaltrexone
- Where
- 60 sites in United States, Australia and 10 more
- Volunteers
- 237 people
- Sponsor
- Bausch Health Americas, Inc.
Terminal Illness
Open-Label Treatment Extension of Protocol MNTX 302
This is a 3 month open-label extension study that allows patients who completed Protocol MNTX 302 to receive SC MNTX.
- Trial name
- NCT01367613
- Testing
- SC Methylnaltrexone
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Bausch Health Americas, Inc.